Abstract:Summary Respiratory syncytial virus (RSV), an RNA virus spread by droplet infection that affects all ages, is increasingly recognised as an important pathogen in adults, especially among older people living with comorbidities. Distinguishing RSV from other acute viral infections on clinical grounds alone, with sufficient precision to be clinically useful, is not possible. The reference standard diagnosis is by PCR: point-of-care tests perform less well with lower viral loads. Testing samples from a single respiratory tract site could result in underdetection. RSV is identified in 6–11% of outpatient respiratory tract infection (RTI) consultations in older adults (≥60 years, or ≥65 years, depending on the study) and accounts for 4–11% of adults (≥18 years) hospitalised with RTI, with 6–15% of those hospitalised admitted to intensive care, and 1–12% of all adults hospitalised with RSV respiratory tract infection dying. Community-based studies estimate the yearly incidence of RSV infection at around 3–7% in adults aged 60 years and older in high-income countries. Although RSV accounts for a similar disease burden as influenza in adults, those hospitalised with severe RSV disease are typically older (most ≥60 years) and have more comorbidities, more respiratory symptoms, and are frequently without fever. Long-term sequelae are common and include deterioration of underlying disease (typically heart failure and COPD). There are few evidence-based RSV-specific treatments currently available, with supportive care being the main modality. Two protein subunit vaccines for protection from severe RSV in adults aged 60 years and older were licensed in 2023, and a third—an mRNA-based vaccine—recently gained market approval in the USA. The phase 3 studies in these three vaccines showed good protection against severe disease. Data on real-world vaccine effectiveness in older adults, including subgroups at high risk for RSV-associated hospitalisation, are needed to establish the best use of these newly approved RSV vaccines. New diagnostics and therapeutics are being developed, which will also need rigorous evaluation within their target populations to ensure they are used only for those in whom there is evidence of improved outcomes. There is an urgent need to reconceptualise this illness from one that is serious in children, but far less important than influenza in older people, to thinking of RSV as also a major risk to health for older people that needs targeted prevention and treatment.

Having the conversation: Individualizing RSV vaccination in older patients

Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population

RSV vaccination in older adults: Addressing vaccine hesitancy using the 3C model

From Forgotten Pathogen to Target for New Vaccines: What Clinicians Need to Know about Respiratory Syncytial Virus Infection in Older Adults

Respiratory Syncytial Virus Infection in Older Adults: An Update

The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein

Preventing respiratory syncytial virus in older adults

Why the UK is vaccinating its older adult population against RSV-what geriatricians should know

Respiratory syncytial virus infections in adults: a narrative review

Tackling the burden of RSV

An Overview on Disease Burden and Management of Respiratory Syncytial Virus Infections in Older Adults in the Asia‐Pacific Region

Unveiling the spectrum of Respiratory Syncytial Virus disease in Adults: from Community to Hospital

RSV prevention options for infants and older adults: A specific expanding competitive arena

Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost-utility analysis

Three RSV vaccines now recommended for many older adults; what about travellers?

Respiratory Syncytial Virus Vaccines: Analysis of Pre-Marketing Clinical Trials for Immunogenicity in the Population over 50 Years of Age

Review of respiratory syncytial virus infection among older adults and transplant recipients

Respiratory Syncytial Virus (RSV) Hospitalizations in the Elderly in a Tertiary Care Hospital in Southern Italy as a Useful Proxy for Targeting Vaccine Preventive Strategies

Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus

Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

RSV vaccination strategies for high-risk patients 2023: a collaborative position paper by leading German medical societies and organizations